When dealing with recurring mucinous appendiceal adenocarcinoma, undergoing repeat cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) can be a game-changer. This study from MD Anderson Cancer Center reveals that patients who opt for repeat CRS/HIPEC enjoy similar recurrence-free survival compared to those initially treated, and even better overall survival than patients relying solely on systemic chemotherapy. These findings emphasize the potential benefits of this treatment strategy, especially when administered by experienced teams in high-volume centers.
Journal Article by Bhutiani N, Grotz TE (…) Fournier KF et 12 al. in Ann Surg Oncol
© 2023. The Author(s).